DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2070
INDEX
Salivary secretion, muscarinic
receptors and, 222
Salmeterol, 292f, 293
arrhythmias caused by, 832
Salsalate, structure of, 977f
SALURON (hydroflumethiazide), 688t
SAM. See S-adenosyl-methionine
(SAM)
SAMSCA (tolvaptan), 714, 800
Saquinavir, 1626t
absorption of, 1649
antiviral activity of, 1644–1646
chemistry of, 1644–1646
distribution of, 1649
drug interactions with, 1649
elimination of, 1649
mechanism of action of, 1649
precautions with, 1649
structure of, 1648f
therapeutic uses of, 1649
untoward effects, 1649
Saquinavir, ABC transporters and, 105t
Sarcoidosis, 1816
antimalarials for, 1819
methotrexate for, 1820
Sarcoma
osteogenic, drugs for, 1668t–1670t
soft-tissue, drugs for, 1668t–1670t
Sargramostim, 1745, 1073–1074
Sarin, 239, 243
Saturable elimination, 34
Saturable protein binding, 33–34
Saxitoxin, 182–183, 575
SC-558, structure of, 963f
Scabies, treatment of, 1818–1819
Scap. See Sterol regulatory element–
binding protein (SREBP)
cleavage activating protein
Scatchard plot, 95
Scavenger receptors, 883–884
SCH530348, 871, 872
antiplatelet effects, site of action,
868f
Schedules, controlled substance, 1882t
Schistosomiasis, 1448–1449
Schizophrenia
dopamine receptor antagonists and,
358
treatment of, 422
Sclera, 1774, 1776f, 1777–1778
Scleritis, fungal, 1783
Scleroderma renal crisis, ACE
inhibitors in, 735
Scleromyxedema, cyclophosphamide
for, 1821
Scopine, 226
Scopolamine
central nervous system and, 230,
233
chemistry of, 226–227
history of, 226
mechanism of action of, 227
for motion sickness, 233
for prevention of motion sickness,
920, 923
structure-activity relationship, 227
structure of, 227f
therapeutic uses of, 923
transdermal, 233
for uveitis, 1788
Screening, of potential drug
compounds, 4
SEASONALE (ethinyl
estradiol/levonorgesterol),
1834, 1836t
SEASONIQUE (ethinyl
estradiol/levonorgesterol),
1834, 1836t
Seborrrheic dermatitis, keratolytics for,
1829
Secobarbital, 471t
Secondary active transport, 94–95, 94f
Second messengers, 55–58
Secretions, muscarinic antagonists and,
229
Sedation, H 1
receptor antagonists for,
923
Sedative-hypnotics, history of,
457–458
Sedative-hypnotic toxidrome, 83t
SEH. See Soluble epoxide hydrolase
(sEH)
Seizures. See also Antiepileptic drugs
absence, 588–589
classification of, 583–585
myoclonic, 605
Selection, polymorphism, 151
Selective estrogen receptor
downregulators (SERDs),
1756, 1759–1760
Selective estrogen receptor modulators
(SERMs), 1299–1300,
1756–1759. See also
Tamoxifen
Selective serotonin reuptake inhibitors
(SSRIs)
arrhythmias caused by, 832
for menopausal symptoms, 1840
for pruritus, 1828t
Selective serotonin-reuptake inhibitors
(SSRIs), 405, 408
adverse effects of, 410–411
Selective serotonin-reuptake inhibitors
(SSRIs) (Cont.):
disposition of, 409t
drug interactions with, 412
transporters and, 90
Selegiline
adrenergic receptors and, 207t
dosage of, 403t, 614t
pharmacokinetics of, 1886t
side effects of, 403t
therapeutic uses of, for
parkinsonism, dosage of,
614t
SEMPREX-D (acrivastine), 921t
Senger’s syndrome, 102t
Sensitization, addiction and, 653
Sepsis, gentamicin for, 1516
SERAX (oxazepam), 466t
SERDs. See Selective estrogen
receptor downregulators
(SERDs)
Serine-threonine kinases, 61–63
SERMs. See Selective estrogen
receptor modulators
(SERMs)
SEROPHENE (clomiphene citrate),
1841–1843
Serotonin
actions of, 340–343
aggression and, 343
anxiety and, 343
cardiovascular system and,
340–341
in central nervous system, 384
central nervous system and,
341–342
chemistry, 335
depression and, 343
electrophysiology of, 342–343
gastrointestinal tract and, 341, 1326
history of, 335
impulsivity and, 343
inactivation of, 336f
in inflammation, 960
metabolism of, 335–337
multiple receptors, 337–340
pharmacological manipulation of, in
tissue, 343–344
physiological functions of,
337–344
platelets and, 340
as pruritogen, 1815
receptor subtypes, 338t
sleep-wake cycle and, 343
sources, 335
synthesis of, 335–337